Atlas Trials

Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

Clinical trial NCT01364415 · COMPLETED

Trial details

NCT number
NCT01364415
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Neuroendocrine Tumors
Start date
2011-08-01
Primary completion
2016-04-01
Enrollment
29

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.